Key Details
Price
$0.32Annual Revenue
$420.00 KAnnual ROE
-214.40%Beta
-0.38Events Calendar
Next earnings date:
Mar 19, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 19, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 18, 2023Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024.
Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $6.60 per share a year ago.
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) held its Q1 2024 Earnings Call on May 14, 2024 at 4:30 PM ET. Present on the call were Grace Kim - Investor Relations, Spiro Rombotis - President and CEO, Brian Schwartz - Chief Medical Officer, and Paul McBarron - Executive Vice President of Finance & COO. The conference call began with a welcome from the operator and all participants were in a listen-only mode.
Cyclacel Pharmaceuticals' stock is surging today following the company's decision to withdraw a public offering that was initially filed in March, as reported in an SEC filing.
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
FAQ
- What is the ticker symbol for Cyclacel Pharmaceuticals?
- Does Cyclacel Pharmaceuticals pay dividends?
- What sector is Cyclacel Pharmaceuticals in?
- What industry is Cyclacel Pharmaceuticals in?
- What country is Cyclacel Pharmaceuticals based in?
- When did Cyclacel Pharmaceuticals go public?
- Is Cyclacel Pharmaceuticals in the S&P 500?
- Is Cyclacel Pharmaceuticals in the NASDAQ 100?
- Is Cyclacel Pharmaceuticals in the Dow Jones?
- When was Cyclacel Pharmaceuticals's last earnings report?
- When does Cyclacel Pharmaceuticals report earnings?
- Should I buy Cyclacel Pharmaceuticals stock now?